Phase 2 Start
FLNA: Phase 2 Start: A Multicenter, Open-label, Randomized Controlled Clinical Study Comparing the Efficacy and Safety of
October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Filana Therapeutics Inc. (FLNA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Multicenter, Open-label, Randomized Controlled Clinical Study Comparing the Efficacy and Safety of
- Indication
- Breast Cancer